Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 232

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Nine patients with anti‐neutrophil cytoplasmic antibody‐positive vasculitis successfully treated with rituximab

Open access
ERIKSSON, P. · 2005 · Journal of Internal Medicine

Abstract

: Objectives. Rituximab (RIT) is a monoclonal anti‐CD20 antibody, which depletes B‐lymphocytes but not plasma cells. RIT is used for treatment of B‐cell lymphomas, but has also shown beneficial effects in autoimmune diseases. In this case series RIT was used in anti‐neutrophil cytoplasmic antibody (ANCA)‐positive vasculitis. Design. Case series with a structured follow‐up of treated patients. Setting. Departments of Nephrology and Rheumatology of a university hospital. Subjects. Two women with myeloperoxidase‐ANCA‐positive microscopic polyangiitis and seven patients (five men and two women) with proteinase 3‐ANCA‐positive Wegener's granulomatosis. All patients were resistant to conventional therapy or had relapsed repeatedly after cessation of cyclophosphamide (Cyc). Interventions. The cases were treated with intravenous infusions of RIT once a week two times (three cases) or four times (six cases). To prevent formation of antibodies to RIT, mycophenolate mofetil (five patients), azathioprine (one patient), or a short course of Cyc (two patients) were added or allowed to continue. Main outcome measures. Remission at 6 months assessed with Birmingham vasculitis activity score. The cases were followed 6–24 months and relapse rate was also noted. Results. Eight of nine patients responded completely and one case responded partially. Pulmonary X‐ray improved (four cases), progress of lower extremity gangrene stopped (one case), remission of neuropathy was stable (one patient), renal vasculitis went into remission (two cases), and severe musculoskeletal pain improved (one case). Minor relapse in the nose occurred in two cases. No adverse events or major infections were noted. Conclusion. RIT seems promising and safe in ANCA‐positive vasculitis, and controlled studies should be conducted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2796.2005.01494.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 232

Metadata

Authors
ERIKSSON, P.
Venue
Journal of Internal Medicine
Publisher
Wiley
Published
2005-05-23
Volume
257
Issue
6
Pages
540-548
ISSN
  • 0954-6820 (ISSN-L)
  • 1365-2796
OpenAlex
W2023473273
Cited by
232
References
2
FWCI
23.68
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nine patients with anti‐neutrophil cytoplasmic antibody‐positive vasculitis successfully treated with rituximab. https://app.cochat.ai/papers/10.1111/j.1365-2796.2005.01494.x
The paper
ERIKSSON, P. (2005). Nine patients with anti‐neutrophil cytoplasmic antibody‐positive vasculitis successfully treated with rituximab. Journal of Internal Medicine. https://doi.org/10.1111/j.1365-2796.2005.01494.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.